Biography

Assistant Professor Huseyin Cimen, currently employed at Biotechnology Institute, Gebze Technical University, Kocaeli, Turkiye, obtained his Ph.D. degree in biochemistry, microbiology, and molecular biology at Eberly College of Science, Penn State University in 2012. He accepted a faculty position 2012 in the Genetics and Bioengineering Department of Yeditepe University, Istanbul, Turkiye. He established the Yeditepe Proteomics and Mass Spectrometry Laboratory (YediPROT) and instruments from the ground with the start-up grant. He started/organized proteomic services for the department and other universities/companies. Then, in October 2023, he moved the YediPROT lab to the Biotechnology Institute at Gebze Technical University.

Research in the lab deals with;

_ Mechanistic study for complementary treatments or characterized plant extracts (3-bromopyruvate, dichloroacetate, sodium borate, berberine, curcumin) applied on different cancer cell-tissue culture models to prevail their effect on drug resistance (formation or relapse) and post-translational modifications (Sirtuin – acetylation)

_ Investigation of the relationship between circadian rhythm and mitochondria during drug resistance, particularly the mechanistic examination of the interaction between BMAL1 and mitochondrial inner membrane potential.

_Development of 3D culture models by employing real tissue to study cancer and mechanistic examination of drug efficiency in the presence of complementary treatments.

_In prostate cancer, establish a model to investigate mitochondrial changes upon sodium borate application in 2D vs. 3D culture models.

_Proteomic analyses synergistic effects of molecules similar to 3-bromopyruvate, dichloroacetate, sodium borate, berberine, and curcumin on different cancer cell lines, glioblastoma, neuroblastoma, and renal cell carcinoma.

_Nutriproteomic study for berberine, resveratrol, and quercetin in cancer cells to unravel their effects on mitochondria.

_Mechanistic study for mitochondrial-targeted or –derived peptides (SS31) in neurodegenerative and metabolic diseases and obesity models.